Eyegate Pharmaceuticals Company Profile (NASDAQ:EYEG)

About Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals logoEyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EYEG
  • CUSIP: N/A
  • Web: www.eyegatepharma.com
Capitalization:
  • Market Cap: $21.65 million
  • Outstanding Shares: 10,878,000
Average Prices:
  • 50 Day Moving Avg: $1.99
  • 200 Day Moving Avg: $1.95
  • 52 Week Range: $1.11 - $3.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 2.09
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $853,790.00
  • Price / Sales: 25.35
  • Book Value: ($0.10) per share
  • Price / Book: -19.90
Profitability:
  • EBIDTA: ($13,810,000.00)
  • Return on Equity: -219.82%
  • Return on Assets: -109.13%
Debt:
  • Current Ratio: 1.02%
  • Quick Ratio: 1.02%
Misc:
  • Average Volume: 310,873 shs.
  • Beta: 2.37
  • Short Ratio: 0.31
 

Frequently Asked Questions for Eyegate Pharmaceuticals (NASDAQ:EYEG)

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.39). The firm earned $0.19 million during the quarter, compared to analysts' expectations of $0.22 million. View Eyegate Pharmaceuticals' Earnings History.

Where is Eyegate Pharmaceuticals' stock going? Where will Eyegate Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 1 year target prices for Eyegate Pharmaceuticals' stock. Their predictions range from $6.00 to $10.00. On average, they expect Eyegate Pharmaceuticals' share price to reach $9.00 in the next twelve months. View Analyst Ratings for Eyegate Pharmaceuticals.

Are investors shorting Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 498,225 shares, a decline of 2.9% from the March 31st total of 512,979 shares. Based on an average daily trading volume, of 58,785 shares, the short-interest ratio is presently 8.5 days.

Who are some of Eyegate Pharmaceuticals' key competitors?

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

Who owns Eyegate Pharmaceuticals stock?

Eyegate Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.40%). Company insiders that own Eyegate Pharmaceuticals stock include Morton Goldberg, Stephen From and Ventech Capital Ii. View Institutional Ownership Trends for Eyegate Pharmaceuticals.

Who bought Eyegate Pharmaceuticals stock? Who is buying Eyegate Pharmaceuticals stock?

Eyegate Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Eyegate Pharmaceuticals.

How do I buy Eyegate Pharmaceuticals stock?

Shares of Eyegate Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Eyegate Pharmaceuticals stock cost?

One share of Eyegate Pharmaceuticals stock can currently be purchased for approximately $1.99.

Analyst Ratings

Consensus Ratings for Eyegate Pharmaceuticals (NASDAQ:EYEG) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $9.00 (352.26% upside)

Analysts' Ratings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/6/2016HC WainwrightSet Price TargetBuy$10.00N/AView Rating Details
12/6/2016Chardan CapitalReiterated RatingBuy$6.00N/AView Rating Details
12/1/2016Rodman & RenshawReiterated RatingBuy$10.00N/AView Rating Details
6/28/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Earnings by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Earnings History by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/20173/31/2017($0.39)($0.39)$0.22 million$0.19 millionViewN/AView Earnings Details
8/10/2016Q2 2016($0.31)($0.46)$0.24 millionViewN/AView Earnings Details
5/13/2016Q1 2016($0.25)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Current Year EPS Consensus Estimate: $-1.50 EPS
Next Year EPS Consensus Estimate: $0.95 EPS

Dividends

Dividend History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Insider Ownership Percentage: 26.50%
Institutional Ownership Percentage: 6.43%
Insider Trades by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Insider Trades by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/6/2017Morton GoldbergDirectorSell8,919$3.00$26,757.00View SEC Filing  
9/15/2016Stephen FromInsiderBuy15,000$1.49$22,350.00View SEC Filing  
6/15/2016Morton GoldbergDirectorSell15,000$3.16$47,400.00View SEC Filing  
6/10/2016Ventech Capital IiMajor ShareholderSell28,600$3.04$86,944.00View SEC Filing  
6/8/2016Ventech Capital IiMajor ShareholderSell29,400$3.25$95,550.00View SEC Filing  
6/7/2016Morton GoldbergDirectorSell10,939$3.31$36,208.09View SEC Filing  
2/19/2015(Innoven Partenaires S.A. IpsaMajor ShareholderBuy366,667$6.00$2,200,002.00View SEC Filing  
2/19/2015Paul G ChaneyDirectorBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Latest Headlines for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Source:
DateHeadline
streetinsider.com logoEyegate Pharma (EYEG) Receives Milestone Payment from Valeant (VRX) for EGP-437
www.streetinsider.com - May 23 at 4:49 PM
reuters.com logoBRIEF-EyeGate receives milestone payment from Valeant
www.reuters.com - May 23 at 4:49 PM
finance.yahoo.com logoEyeGate Receives Milestone Payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients
finance.yahoo.com - May 22 at 11:35 AM
finance.yahoo.com logoEyegate Pharma stock surges 11% after receiving Valeant milestone payment
finance.yahoo.com - May 22 at 11:35 AM
americanbankingnews.com logoEyegate Pharmaceuticals Inc (EYEG) Rating Reiterated by Noble Financial
www.americanbankingnews.com - May 19 at 7:18 AM
americanbankingnews.com logoEyegate Pharmaceuticals Inc (EYEG) Announces Earnings Results, Meets Expectations
www.americanbankingnews.com - May 9 at 12:52 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals reports net loss of $2.9 million
www.reuters.com - May 8 at 4:58 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: CombiMatrix and Eyegate Pharmaceuticals
finance.yahoo.com - May 8 at 9:03 AM
finance.yahoo.com logoEyeGate Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 8 at 9:03 AM
reuters.com logoBRIEF-Eyegate files investigational device exemption for pilot study of ocular bandage gel
www.reuters.com - May 5 at 5:19 PM
finance.yahoo.com logoEyeGate Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel
finance.yahoo.com - May 4 at 12:13 PM
americanbankingnews.com logoEyegate Pharmaceuticals Inc (EYEG) Sees Significant Decline in Short Interest
www.americanbankingnews.com - May 4 at 7:04 AM
reuters.com logoBRIEF-EyeGate Pharmaceuticals files for common stock offering - Reuters
www.reuters.com - April 22 at 8:55 AM
americanbankingnews.com logoEyegate Pharmaceuticals (EYEG) Receiving Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 2:05 PM
americanbankingnews.com logoEyegate Pharmaceuticals (EYEG) Earns Media Impact Score of -0.02
www.americanbankingnews.com - April 16 at 9:12 AM
americanbankingnews.com logoEyegate Pharmaceuticals Inc (EYEG) Short Interest Down 40.0% in March
www.americanbankingnews.com - April 15 at 11:56 AM
nasdaq.com logoWhy Is Valeant (VRX) Down 17.7% Since the Last Earnings Report?
www.nasdaq.com - March 31 at 5:13 PM
americanbankingnews.com logoEyegate Pharmaceuticals Inc (EYEG) Sees Large Growth in Short Interest
www.americanbankingnews.com - March 28 at 8:23 AM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Sangamo, Eyegate ... - PR Newswire (press release)
www.prnewswire.com - March 24 at 10:22 PM
globenewswire.com logoEyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, MD and Randall J ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 10:30 PM
finance.yahoo.com logoEyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D.
finance.yahoo.com - March 13 at 11:50 AM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 10 at 11:20 AM
finance.yahoo.com logoEYEG: Several Major Development Milestones Expected in 2017
finance.yahoo.com - March 2 at 5:22 PM
finance.yahoo.com logoEYEGATE PHARMACEUTICALS INC Financials
finance.yahoo.com - March 1 at 4:50 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals reports full-year 2016 financial results - Reuters
www.reuters.com - February 23 at 10:08 PM
prnewswire.com logoValeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post ... - PR Newswire (press release)
www.prnewswire.com - February 23 at 10:08 PM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 23 at 5:07 PM
finance.yahoo.com logoEyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update
finance.yahoo.com - February 23 at 5:07 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals says under license agreement, Valeant to make upfront payment of $4.0 mln - SEC filing
www.reuters.com - February 22 at 5:24 PM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
us.rd.yahoo.com - February 22 at 5:24 PM
thestreet.com logoStock Futures Rise After Walmart, Home Depot Top Earnings Estimates
us.rd.yahoo.com - February 22 at 5:24 PM
thestreet.com logoDow Higher for Eighth Straight Session as Retailers Rise
us.rd.yahoo.com - February 22 at 5:24 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals says under license agreement, Valeant to make upfront payment of $4.0 mln - SEC filing - Reuters
www.reuters.com - February 22 at 9:11 AM
nasdaq.com logoMid-Afternoon Market Update: Dow Surges Over 100 Points - Nasdaq - Nasdaq
www.nasdaq.com - February 22 at 9:11 AM
finance.yahoo.com logoEyeGate Pharmaceuticals Licensing Deal Review and Breakdown
finance.yahoo.com - February 22 at 9:11 AM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial St
biz.yahoo.com - February 8 at 5:39 PM
us.rd.yahoo.com logo4:02 pm Eyegate Pharmaceuticals appoints Sarah Romano, Corporate Controller, as interim CFO
us.rd.yahoo.com - February 7 at 6:18 PM
reuters.com logoBRIEF-EyeGate Pharmaceuticals announces executive promotions
www.reuters.com - February 7 at 3:11 AM
streetinsider.com logoEyegate Pharma (EYEG) Names Sarah Romano as Interim CFO
www.streetinsider.com - February 7 at 3:11 AM
finance.yahoo.com logoEyeGate Pharmaceuticals Announces Executive Promotions
finance.yahoo.com - February 6 at 5:09 PM
finance.yahoo.com logoEYEG: Positive OBG Clinical Data, Larger Study Already Planned
finance.yahoo.com - February 3 at 5:31 PM
streetinsider.com logoEyegate Pharma (EYEG) Reports Encouraging EyeGate OBG Top-Line Results from First-in-Human Pilot Trial - StreetInsider.com
www.streetinsider.com - January 31 at 10:49 PM
247wallst.com logoIs This The Beginning of EyeGate’s Rally?
247wallst.com - January 30 at 5:26 PM
reuters.com logoBRIEF-Eyegate Pharma announces positive top-line data from first-in-human pilot trial of ocular bandage gel
www.reuters.com - January 30 at 12:08 PM
streetinsider.com logoEyegate Pharma (EYEG) Reports Encouraging EyeGate OBG Top-Line Results from First-in-Human Pilot Trial
www.streetinsider.com - January 30 at 12:08 PM
finance.yahoo.com logoEyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects
finance.yahoo.com - January 30 at 12:08 PM
finance.yahoo.com logo8:31 am EyeGate Pharma announces 'positive' top-line data from first-in-human pilot trial of ocular bandage gel in corneal epithelial defects
finance.yahoo.com - January 30 at 12:08 PM

Social

Chart

Eyegate Pharmaceuticals (EYEG) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff